Institut Rosell Purchases LAFTI Probiotic Line from DSM

MONTREAL Institut Rosell-Lallemand completed the acquisition of the LAFTI® probiotic business from DSM. The LAFTI line of probiotic strains has been studied for its benefits to gut health, immune function and childrens health; they have been marketed for six years in dietary supplements and dairy applications. Under terms of the acquisition, DSM Food Specialties retains the dairy portion of the LAFTI business through a license agreement, reflecting the companys strategy to concentrate on food and beverage applications. Institut Rosell will target the dietary supplements market, as the LAFTI strains have shown viability in a range of delivery systems (i.e., capsules, soft gels, tablets) and alone or in combination formulas.

Olivier Clech, vice president for Lallemand Human and Animal Nutrition, commented: DSMs LAFTI range of probiotic strains benefits from an excellent reputation and is endorsed by strong scientific and clinical back-up. Over the years, DSM has developed major partnerships with key players of the health and food industry as well as recognized scientific opinion leaders. The quality and reputation of these strains fits perfectly in our own probiotic portfolio, complementing it with new species, such as Bifidobacterium animalis lactis and offering novel areas of applications such as sport health and athletes recovery.

The LAFTI range of documented probiotics comprises of three strains: Lactobacillus acidophilus LAFTI L10 (L10), Lactobacillus casei LAFTI L26 (L26) and Bifidobacterium animalis lactis LAFTI B94 (B94). There is a patent pending for the application of the LAFTI® strains in the reduction of the impact of winter infections in healthy adults.